Cardiff Oncology, Inc.
NASDAQ:CRDF
2.23 (USD) • At close September 8, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Revenue
| 0.683 | 0.488 | 0.386 | 0.359 | 0.366 |
| Cost of Revenue
| 0 | 0.398 | 0.2 | 0.5 | 11.235 |
| Gross Profit
| 0.683 | 0.488 | 0.186 | -0.141 | -10.869 |
| Gross Profit Ratio
| 1 | 1 | 0.482 | -0.393 | -29.697 |
| Reseach & Development Expenses
| 36.852 | 32.857 | 27.107 | 17.376 | 11.235 |
| General & Administrative Expenses
| 12.482 | 13.043 | 13.181 | 11.838 | 8.216 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 |
| SG&A
| 12.482 | 13.043 | 13.181 | 11.838 | 8.216 |
| Other Expenses
| 0 | 0 | 0 | -0.5 | 0 |
| Operating Expenses
| 49.334 | 45.9 | 40.288 | 28.714 | 19.452 |
| Operating Income
| -48.651 | -45.412 | -39.902 | -28.855 | -19.086 |
| Operating Income Ratio
| -71.231 | -93.057 | -103.373 | -80.376 | -52.148 |
| Total Other Income Expenses Net
| 3.22 | 3.971 | 1.198 | 0.564 | -0.221 |
| Income Before Tax
| -45.455 | -41.441 | -38.704 | -28.291 | -19.307 |
| Income Before Tax Ratio
| -66.552 | -84.92 | -100.269 | -78.805 | -52.751 |
| Income Tax Expense
| -0.024 | 0 | -1.198 | -0.549 | -0.027 |
| Net Income
| -45.431 | -41.441 | -38.704 | -28.291 | -19.28 |
| Net Income Ratio
| -66.517 | -84.92 | -100.269 | -78.805 | -52.678 |
| EPS
| -0.95 | -0.93 | -0.89 | -0.73 | -1.08 |
| EPS Diluted
| -0.95 | -0.93 | -0.89 | -0.73 | -1.08 |
| EBITDA
| -48.247 | -45.014 | -39.666 | -28.404 | -18.839 |
| EBITDA Ratio
| -70.64 | -92.242 | -102.762 | -79.12 | -51.474 |